有村　健    Department   School of Medicine(Tokyo Women's Medical University Hospital), School of Medicine    Position   Assistant Professor
Article types	Original article
Language	English
Peer review	Non peer reviewed
Title	Granulocyte and monocyte apheresis therapy for patients with active ulcerative colitis associated with COVID-19: a case report
Journal	Formal name：Intestinal research Abbreviation：Intest Res ISSN code：15989100/15989100
Domestic / Foregin	Foregin
Volume, Issue, Page	20(1),pp.150-155
Author and coauthor	KOROKU Miki, OMORI Teppei*, KAMBAYASHI Harutaka, MURASUGI Shun, KURIYAMA Tomoko, IKARASHI Yuichi, YONEZAWA Maria, ARIMURA Ken, KARASAWA Kazunori, HANAFUSA, Norio, KAWANA Masatoshi, TOKUSHIGE Katsutoshi
Publication date	2022/01
Summary	Coronavirus disease 2019 (COVID-19), caused by infection with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), is now a pandemic. Although several treatment guidelines have been proposed for patients who have both inflammatory bowel disease and COVID-19, immunosuppressive therapy is essentially not recommended, and the treatment options are limited. Even in the COVID-19 pandemic, adjuvant adsorptive granulocyte and monocyte apheresis may safely bring ulcerative colitis (UC) into remission by removing activated myeloid cells without the use of immunosuppressive therapy. Our patient was a 25-year-old Japanese male with UC and COVID-19. This is the first case report of the induction of UC remission with granulocyte and monocyte apheresis treatment for active UC associated with COVID-19.
DOI	10.5217/ir.2020.00148
PMID	33902268